On May 16, 2018 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that new data from its isocitrate dehydrogenase (IDH) programs will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held June 1-5, 2018 in Chicago (Press release, Agios Pharmaceuticals, MAY 16, 2018, View Source [SID1234526695]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In total, five abstracts led by Agios describing new data from the company’s IDH programs have been accepted for presentation at ASCO (Free ASCO Whitepaper), as well as one abstract led by Celgene Corporation. IDHIFA (enasidenib) is being commercialized in collaboration with Celgene.

The accepted abstracts are listed below and are available online on the ASCO (Free ASCO Whitepaper) conference website: View Source

Oral presentations by Agios:

Title: Phase 1 Study of AG-881, an Inhibitor of Mutant IDH1/IDH2, in Patients with Advanced IDH-mutant Solid Tumors, Including Glioma
Date & Time: Friday, June 1, 2018 from 3:09-3:21 p.m. CT
Oral Abstract Session: Central Nervous System Tumors
Abstract: 2002
Location: S102
Presenter: Ingo K. Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center

Title: Ivosidenib (IVO; AG-120) in Mutant IDH1 Relapsed/Refractory AML: Results of a Phase 1 Study
Date & Time: Saturday, June 2, 2018 from 3:00-3:12 p.m. CT
Oral Abstract Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7000
Location: E450
Presenter: Daniel Aaron Pollyea, M.D., M.S., University of Colorado School of Medicine
This abstract has been selected as part of the "Best of ASCO (Free ASCO Whitepaper)" program to be presented in cities across the country. "Best of ASCO (Free ASCO Whitepaper)" features the top abstracts, highlighting the most cutting-edge science and education from the annual meeting.

Poster presentations by Agios and/or Celgene:

Title: Mutant IDH (mIDH) Inhibitors, Ivosidenib or Enasidenib, with Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)
Poster Session Date & Time: Monday, June 4, 2018 from 8:00-11:30 a.m. CT
Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7042
Poster Board: 102
Poster Location: Hall A
Author: Courtney Denton DiNardo, M.D., University of Texas MD Anderson Cancer Center

Title: AGILE: A Phase 3, Multicenter, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
Poster Session Date & Time: Monday, June 4, 2018 from 8:00-11:30 a.m. CT
Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: TPS7074
Poster Board: 133b
Poster Location: Hall A
Author: Eytan Stein, M.D., Memorial Sloan Kettering Cancer Center

Title: Pharmacokinetics/pharmacodynamics (PK/PD) of Ivosidenib in Patients with IDH1-mutant Advanced Solid Tumors from a Phase 1 Study
Poster Session Date & Time: Monday, June 4, 2018 from 8:00-11:30 a.m. CT
Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Abstract: 2577
Poster Board: 403
Poster Location: Hall A
Author: Bin Fan, Ph.D., Agios Pharmaceuticals

Title: Clinical pharmacokinetics/pharmacodynamics (PK/PD) of Ivosidenib in Patients with IDH1-mutant Advanced Hematologic Malignancies from a Phase 1 Study
Poster Session Date & Time: Monday, June 4, 2018 from 8:00-11:30 a.m. CT
Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Abstract: 2581
Poster Board: 407
Poster Location: Hall A
Author: David Dai, Ph.D., Agios Pharmaceuticals